Benjamin Samstein, Adam Griesemer, Daniel Cherqui, Tarek Mansour, Joseph Pisa, Anna Yegiants, Alyson N. Fox, James V. Guarrera, Tomoaki Kato, Karim J. Halazun, Jean Emond – 17 March 2015 – Living donor liver transplantation has failed to become a major means of transplantation in the United States, where <5% of the transplants are performed with living donors. At least 30% to 50% of the complications of donor hepatectomy appear to be related to abdominal wall trauma, including hernia, bowel obstruction, and chronic abdominal discomfort.

Roongruedee Chaiteerakij, Xiaodan Zhang, Benyam D. Addissie, Essa A. Mohamed, William S. Harmsen, Paul J. Theobald, Brian E. Peters, Joseph G. Balsanek, Melissa M. Ward, Nasra H. Giama, Catherine D. Moser, Abdul M. Oseini, Naoki Umeda, Sudhakar Venkatesh, Denise M. Harnois, Michael R. Charlton, Hiroyuki Yamada, Shinji Satomura, Alicia Algeciras‐Schimnich, Melissa R. Snyder, Terry M. Therneau, Lewis R. Roberts – 17 March 2015 – Growing evidence suggests that pretransplant alpha‐fetoprotein (AFP) predicts outcomes of hepatocellular carcinoma (HCC) patients treated with liver transplantation.

Christian Toso, Glenda Meeberg, Roberto Hernandez‐Alejandro, Jean‐François Dufour, Paul Marotta, Pietro Majno, Norman M. Kneteman – 17 March 2015 – The selection of liver transplantation (LT) candidates with hepatocellular carcinoma (HCC) is currently validated based on Milan criteria. The use of extended criteria has remained a matter of debate, mainly because of the absence of prospective validation. The present prospective study recruited patients according to the previously proposed total tumor volume (TTV; ≤115 cm3)/alpha‐fetoprotein (AFP; ≤400 ng/mL) score.

Javier Vaquero, Rafael Bañares – 17 March 2015

Patrice N. Mimche, Lauren M. Brady, Christian F. Bray, Choon M. Lee, Manoj Thapa, Thayer P. King, Kendra Quicke, Courtney D. McDermott, Sylvie M. Mimche, Arash Grakoui, Edward T. Morgan, Tracey J. Lamb – 17 March 2015 – Beyond the well‐defined role of the Eph (erythropoietin‐producing hepatocellular) receptor tyrosine kinases in developmental processes, cell motility, cell trafficking/adhesion, and cancer, nothing is known about their involvement in liver pathologies.

Constantine J. Karvellas, R. Todd Stravitz, Holly Battenhouse, William M. Lee, Michael L. Schilsky, for the US Acute Liver Failure Study Group – 16 March 2015

Andrea F. DiMartini, Mary Amanda Dew, Zeeshan Butt, Mary Ann Simpson, Daniela P. Ladner, Abigail R. Smith, Peg Hill‐Callahan, Brenda W. Gillespie – 16 March 2015 – Although sexual functioning is an important facet of a living donor's quality of life, it has not received an extensive evaluation in this population. Using data from the Adult‐to‐Adult Living Donor Liver Transplantation Cohort Study, we examined donor sexual functioning across the donation process from the predonation evaluation to 3 months and 1 year after donation.

Michael L. Volk, Nathan Goodrich, Jennifer C. Lai, Christopher Sonnenday, Kerby Shedden – 16 March 2015 – Organ offers in liver transplantation are high‐risk medical decisions with a low certainty of whether a better liver offer will come along before death. We hypothesized that decision support could improve the decision to accept or decline. With data from the Scientific Registry of Transplant Recipients, survival models were constructed for 42,857 waiting‐list patients and 28,653 posttransplant patients from 2002 to 2008.

Gregory C. Wilson, Richard S. Hoehn, Audrey E. Ertel, Koffi Wima, R. Cutler Quillin, Sam Hohmann, Flavio Paterno, Daniel E. Abbott, Shimul A. Shah – 13 March 2015 – The rate and causes of hospital readmissions after liver transplantation (LT) remain largely unknown in the United States.

Maximilian von Heesen, Stefan Dold, Simon Müller, Claudia Scheuer, Otto Kollmar, Martin K. Schilling, Michael D. Menger, Mohammed R. Moussavian – 13 March 2015 – Major hepatectomy or small‐for‐size liver transplantation may result in postoperative liver failure. So far, no treatment is available to improve liver regeneration. Herein, we studied whether cilostazol, a selective phosphodiesterase III inhibitor, is capable of improving liver regeneration after major hepatectomy.